CLEVELAND — Ganeden Biotech has been issued U.S. patent No. 8,697,055 B2 that protects the use of all Bacillus coagulans probiotic strains, including the company’s GanedenBC30, in coffee, tea and cereal applications.
“This patent goes a long way toward supporting our partners in their quest to launch new brands and revolutionize existing ones,” said Andy Lefkowitz, chief executive officer of Cleveland-based Ganeden Biotech.
Spore-forming probiotic organisms such as GanedenBC30 (Bacillus coagulans GBI-30, 6086) have been shown to withstand harsh manufacturing processes, including those required to make hot tea, coffee and cereal, according to Ganeden Biotech. The organisms’ effectiveness may be linked to a naturally occurring layer of organic material (spore), which protects the bacteria’s genetic core throughout the manufacturing process and the transit into the human gut.
Mintz Levin assisted Ganeden Biotech in the patent filing process.
“Our patent attorneys at Mintz Levin continue to produce superior legal counsel that strengthens our market position,” said David Keller, vice-president of scientific operations at Ganeden Biotech.